Repare Therapeutics Inc. has provided an update regarding its previously announced agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. Under the terms of the deal, Xeno will acquire all issued and outstanding common shares of Repare. The company disclosed that, following the announcement of the agreement, major shareholders including entities affiliated with BVF Partners L.P., Blue Owl Healthcare Opportunities, and OrbiMed have entered into support and voting agreements to back the transaction. With the inclusion of support from Repare's directors and executive officers, shareholders representing approximately 40% of the company's shares have now agreed to support the deal.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120902912) on November 20, 2025, and is solely responsible for the information contained therein.